Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients
Compose a Response to This Article
Other responses
No responses have been published for this article.
